Suggested remit - To appraise the clinical and cost effectiveness of Abicipar pegol within its marketing authorisation for treating wet age-related macular degeneration
Status Proposed
Process STA 2018
ID number 1533

Project Team

Project lead Emily Richards

Email enquiries


Key events during the development of the guidance:

Date Update
29 May 2019 - 26 June 2019 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance